JP2016503793A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503793A5 JP2016503793A5 JP2015549643A JP2015549643A JP2016503793A5 JP 2016503793 A5 JP2016503793 A5 JP 2016503793A5 JP 2015549643 A JP2015549643 A JP 2015549643A JP 2015549643 A JP2015549643 A JP 2015549643A JP 2016503793 A5 JP2016503793 A5 JP 2016503793A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- optionally substituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 20
- 239000011780 sodium chloride Substances 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261738822P | 2012-12-18 | 2012-12-18 | |
US61/738,822 | 2012-12-18 | ||
PCT/US2013/076214 WO2014100228A1 (en) | 2012-12-18 | 2013-12-18 | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019109822A Division JP6852118B2 (ja) | 2012-12-18 | 2019-06-12 | 向神経活性19−アルコキシ−17−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016503793A JP2016503793A (ja) | 2016-02-08 |
JP2016503793A5 true JP2016503793A5 (pt-PT) | 2017-02-02 |
JP6542127B2 JP6542127B2 (ja) | 2019-07-10 |
Family
ID=50979162
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015549643A Active JP6542127B2 (ja) | 2012-12-18 | 2013-12-18 | 向神経活性19−アルコキシ−17−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
JP2019109822A Active JP6852118B2 (ja) | 2012-12-18 | 2019-06-12 | 向神経活性19−アルコキシ−17−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
JP2021038515A Active JP7241792B2 (ja) | 2012-12-18 | 2021-03-10 | 向神経活性19-アルコキシ-17-置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
JP2023034402A Pending JP2023071910A (ja) | 2012-12-18 | 2023-03-07 | 向神経活性19-アルコキシ-17-置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019109822A Active JP6852118B2 (ja) | 2012-12-18 | 2019-06-12 | 向神経活性19−アルコキシ−17−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
JP2021038515A Active JP7241792B2 (ja) | 2012-12-18 | 2021-03-10 | 向神経活性19-アルコキシ-17-置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
JP2023034402A Pending JP2023071910A (ja) | 2012-12-18 | 2023-03-07 | 向神経活性19-アルコキシ-17-置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
Country Status (27)
Country | Link |
---|---|
US (7) | US9676812B2 (pt-PT) |
EP (3) | EP4086270A1 (pt-PT) |
JP (4) | JP6542127B2 (pt-PT) |
KR (3) | KR102265408B1 (pt-PT) |
CN (3) | CN109970833B (pt-PT) |
AU (5) | AU2013361485B2 (pt-PT) |
BR (1) | BR112015014397B1 (pt-PT) |
CA (1) | CA2895513C (pt-PT) |
CY (1) | CY1121150T1 (pt-PT) |
DK (1) | DK2935307T3 (pt-PT) |
ES (2) | ES2680582T3 (pt-PT) |
HK (1) | HK1216255A1 (pt-PT) |
HR (1) | HRP20181048T1 (pt-PT) |
HU (1) | HUE039057T2 (pt-PT) |
IL (3) | IL310501A (pt-PT) |
LT (1) | LT2935307T (pt-PT) |
MX (2) | MX365644B (pt-PT) |
NZ (2) | NZ709211A (pt-PT) |
PH (2) | PH12018502141A1 (pt-PT) |
PL (1) | PL2935307T3 (pt-PT) |
PT (2) | PT2935307T (pt-PT) |
RS (1) | RS57390B1 (pt-PT) |
RU (1) | RU2663665C2 (pt-PT) |
SG (3) | SG10201706063UA (pt-PT) |
SI (2) | SI2935307T1 (pt-PT) |
TR (1) | TR201808616T4 (pt-PT) |
WO (1) | WO2014100228A1 (pt-PT) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008006888A (es) | 2005-11-28 | 2008-09-30 | Marinus Pharmaceuticals | Formulas y metodos para la manufactura y uso de la ganaxolona. |
ES2951664T3 (es) | 2011-09-08 | 2023-10-24 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
CN113234114A (zh) | 2011-10-14 | 2021-08-10 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
CN112472814A (zh) | 2012-01-23 | 2021-03-12 | 萨奇治疗股份有限公司 | 神经活性类固醇制剂和治疗中枢神经系统障碍的方法 |
RS57390B1 (sr) | 2012-12-18 | 2018-09-28 | Univ Washington | Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja |
EP3932932A1 (en) | 2013-03-13 | 2022-01-05 | Sage Therapeutics, Inc. | Neuroactive steriods and methods of use thereof |
WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
CN112110976B (zh) | 2013-04-17 | 2023-08-29 | 萨奇治疗股份有限公司 | 刺激神经活性的19-去甲类固醇及其使用方法 |
SI2986623T1 (sl) | 2013-04-17 | 2019-03-29 | Sage Therapeutics, Inc. | 19-NOR C3,3-disubstituirani C21-N-pirazolil steroidi in metode njhove uporabe |
WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
DK3021852T3 (da) | 2013-07-19 | 2021-03-15 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser deraf |
WO2015027227A1 (en) | 2013-08-23 | 2015-02-26 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
EP4306114A1 (en) | 2014-06-18 | 2024-01-17 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
SG10202009859YA (en) | 2014-10-16 | 2020-11-27 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
WO2016061537A1 (en) | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
EP3250210B1 (en) * | 2015-01-26 | 2020-12-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
EP4155314A1 (en) * | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
MY197698A (en) | 2015-07-06 | 2023-07-06 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
MA42409A (fr) | 2015-07-06 | 2018-05-16 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
RU2021100620A (ru) | 2015-07-06 | 2021-01-29 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
EA036155B1 (ru) | 2015-10-16 | 2020-10-06 | Маринус Фармасьютикалс, Инк. | Инъекционные составы нейростероида, содержащие наночастицы |
MA43284A (fr) * | 2015-11-20 | 2018-09-26 | Sage Therapeutics Inc | Composés et leurs méthodes d'utilisation |
CN109414444A (zh) | 2016-03-08 | 2019-03-01 | 萨奇治疗股份有限公司 | 神经活性类固醇、其组合物及用途 |
LT3436022T (lt) | 2016-04-01 | 2022-06-27 | Sage Therapeutics, Inc. | Oksisteroliai ir jų panaudojimo būdai |
WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
ES2884071T3 (es) | 2016-07-07 | 2021-12-10 | Sage Therapeutics Inc | 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA |
IL264129B2 (en) | 2016-07-11 | 2024-05-01 | Sage Therapeutics Inc | C20, C17 and C21 converted neuroactive steroids and methods of using them |
EP3481844B1 (en) | 2016-07-11 | 2024-04-17 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
EP4233861A3 (en) | 2016-08-11 | 2023-10-11 | Ovid Therapeutics, Inc. | Compositions for treatment of essential tremor |
JP2019524853A (ja) | 2016-08-23 | 2019-09-05 | セージ セラピューティクス, インコーポレイテッド | 結晶性19−ノルc3,3−二置換c21−n−ピラゾリルステロイド |
US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
CN110023323A (zh) | 2016-09-30 | 2019-07-16 | 萨奇治疗股份有限公司 | C7取代的氧固醇及其作为nmda调节剂的方法 |
CA3041088C (en) | 2016-10-18 | 2024-05-21 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
MA46565A (fr) | 2016-10-18 | 2019-08-28 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
KR20200096596A (ko) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
CN109988210B (zh) * | 2017-12-30 | 2022-05-17 | 天津药业研究院股份有限公司 | 一种黄体酮和黄体酮中间体的制备方法 |
AU2019357040A1 (en) | 2018-10-12 | 2021-05-20 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders |
CN109289095B (zh) * | 2018-11-23 | 2021-03-26 | 淮海工学院 | 一种含盐酸利多卡因的肠镜凝胶剂及其制备方法 |
US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
CR20210629A (es) | 2019-05-31 | 2022-03-22 | Sage Therapeutics Inc | Esteroides neuroactivos y composiciones de estos |
MX2022001553A (es) | 2019-08-05 | 2022-04-18 | Marinus Pharmaceuticals Inc | Ganaxolona para su uso en el tratamiento del estado epileptico. |
US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
CN114828889A (zh) | 2019-12-06 | 2022-07-29 | 马瑞纳斯制药公司 | 用于治疗结节性硬化症的加奈索酮 |
MX2022011804A (es) | 2020-03-25 | 2023-03-09 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias. |
CN117801047A (zh) * | 2023-01-19 | 2024-04-02 | 北京华睿鼎信科技有限公司 | 神经甾体衍生物及其用途 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB820780A (en) * | 1954-12-08 | 1959-09-23 | Syntex Sa | Cyclopentanophenanthrene derivatives |
US2856415A (en) * | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
BE632431A (pt-PT) * | 1962-05-16 | |||
US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
US4239681A (en) * | 1974-04-15 | 1980-12-16 | Richardson-Merrell Inc. | Androst-4-en-19-ols |
US4139617A (en) * | 1974-05-13 | 1979-02-13 | Richardson-Merrell Inc. | 19-Oxygenated-androst-5-enes for the enhancement of libido |
US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
US4022769A (en) * | 1974-05-13 | 1977-05-10 | Richardson-Merrell Inc. | Androst-4-en-19-ones |
DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
MA18433A1 (fr) * | 1978-05-26 | 1979-12-31 | Ciba Geigy Ag | Procede pour la synthese de la chaine laterale hydroxyacetyle de steroides du type pregnagne, nouveaux 21-hydroxy-20-oxo-17 alpha-pregnagnes et produits pharmaceutiques en renfermant |
US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
US4495102A (en) * | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
US5661141A (en) * | 1995-03-27 | 1997-08-26 | Petrow; Vladimir | 19-oxygenated steroids as therapeutic agents |
GEP20012530B (en) * | 1995-06-06 | 2001-09-25 | Cocensys Inc | Neuroactive Steroids of the Androstane and Pregnane Series |
WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
EP1330467B1 (en) | 2000-11-03 | 2007-05-02 | Washington University | Modified, hydroxy-substituted aromatic structures having cytoprotective activity |
GR1003861B (el) * | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
CA2520142C (en) | 2003-03-24 | 2011-01-04 | Sterix Limited | Oestrogen derivatives as inhibitors of steroid sulphatase |
CN1281561C (zh) * | 2003-04-23 | 2006-10-25 | 中国科学院上海有机化学研究所 | 一种具有1,6-亚甲基-[10]-轮烯基本骨架的化合物及其用途 |
WO2005000869A1 (en) * | 2003-05-29 | 2005-01-06 | Washington University | Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids |
JP2007512344A (ja) * | 2003-11-24 | 2007-05-17 | メルク エンド カムパニー インコーポレーテッド | エストロゲン受容体調節剤 |
CN100376685C (zh) * | 2005-01-14 | 2008-03-26 | 天津科技大学 | 微生物转化法制备雌酚酮的方法 |
JP2008538748A (ja) * | 2005-04-07 | 2008-11-06 | ハイシアム, インコーポレイテッド | 不安、物質乱用及び依存の予防のための改良型方法及び組成物 |
DE102007027636A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
US8575375B2 (en) * | 2007-06-15 | 2013-11-05 | Research Triangle Institute | Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties |
GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
US20130303500A1 (en) | 2010-07-30 | 2013-11-14 | Medexis S.A. | Compounds and methods for treating neoplasia |
US20120214987A1 (en) | 2010-12-15 | 2012-08-23 | Yu Ge | Methods and compounds for preparing 3alpha-oxygen substituted steroids |
US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
US9851309B2 (en) | 2011-03-23 | 2017-12-26 | Satoshi Watabe | Ultra-high-sensitive assay of protein and nucleic acid and kit, and novel enzyme substrate |
US20150175651A1 (en) * | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US9765110B2 (en) * | 2012-10-08 | 2017-09-19 | Washington University | Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
RS57390B1 (sr) | 2012-12-18 | 2018-09-28 | Univ Washington | Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja |
US9562026B2 (en) * | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
WO2015027227A1 (en) * | 2013-08-23 | 2015-02-26 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
-
2013
- 2013-12-18 RS RS20180807A patent/RS57390B1/sr unknown
- 2013-12-18 PH PH12018502141A patent/PH12018502141A1/en unknown
- 2013-12-18 CN CN201811630997.3A patent/CN109970833B/zh active Active
- 2013-12-18 KR KR1020197018089A patent/KR102265408B1/ko active IP Right Grant
- 2013-12-18 BR BR112015014397-0A patent/BR112015014397B1/pt active IP Right Grant
- 2013-12-18 US US14/652,717 patent/US9676812B2/en active Active
- 2013-12-18 NZ NZ709211A patent/NZ709211A/en unknown
- 2013-12-18 SG SG10201706063UA patent/SG10201706063UA/en unknown
- 2013-12-18 RU RU2015129546A patent/RU2663665C2/ru active
- 2013-12-18 ES ES13865411.6T patent/ES2680582T3/es active Active
- 2013-12-18 AU AU2013361485A patent/AU2013361485B2/en active Active
- 2013-12-18 KR KR1020217017732A patent/KR102400891B1/ko active IP Right Grant
- 2013-12-18 SG SG11201504848QA patent/SG11201504848QA/en unknown
- 2013-12-18 SI SI201331092T patent/SI2935307T1/en unknown
- 2013-12-18 IL IL310501A patent/IL310501A/en unknown
- 2013-12-18 PT PT138654116T patent/PT2935307T/pt unknown
- 2013-12-18 JP JP2015549643A patent/JP6542127B2/ja active Active
- 2013-12-18 EP EP22166199.4A patent/EP4086270A1/en active Pending
- 2013-12-18 SG SG10201809638YA patent/SG10201809638YA/en unknown
- 2013-12-18 LT LTEP13865411.6T patent/LT2935307T/lt unknown
- 2013-12-18 CN CN201380072706.2A patent/CN105026415B/zh active Active
- 2013-12-18 CA CA2895513A patent/CA2895513C/en active Active
- 2013-12-18 CN CN202210026684.7A patent/CN114605486A/zh active Pending
- 2013-12-18 EP EP18162373.7A patent/EP3392260B1/en active Active
- 2013-12-18 PL PL13865411T patent/PL2935307T3/pl unknown
- 2013-12-18 MX MX2015007900A patent/MX365644B/es active IP Right Grant
- 2013-12-18 TR TR2018/08616T patent/TR201808616T4/tr unknown
- 2013-12-18 DK DK13865411.6T patent/DK2935307T3/en active
- 2013-12-18 PT PT181623737T patent/PT3392260T/pt unknown
- 2013-12-18 ES ES18162373T patent/ES2933987T3/es active Active
- 2013-12-18 HU HUE13865411A patent/HUE039057T2/hu unknown
- 2013-12-18 NZ NZ739760A patent/NZ739760A/en unknown
- 2013-12-18 EP EP13865411.6A patent/EP2935307B1/en active Active
- 2013-12-18 US US14/132,386 patent/US9630986B2/en active Active
- 2013-12-18 WO PCT/US2013/076214 patent/WO2014100228A1/en active Application Filing
- 2013-12-18 SI SI201332021T patent/SI3392260T1/sl unknown
- 2013-12-18 KR KR1020157019442A patent/KR101993899B1/ko active IP Right Grant
-
2015
- 2015-06-18 IL IL239501A patent/IL239501B/en active IP Right Grant
- 2015-06-18 PH PH12015501404A patent/PH12015501404A1/en unknown
- 2015-06-18 MX MX2019006739A patent/MX2019006739A/es unknown
-
2016
- 2016-04-14 HK HK16104261.6A patent/HK1216255A1/zh unknown
-
2017
- 2017-03-15 US US15/459,492 patent/US10342809B2/en active Active
- 2017-05-04 US US15/586,853 patent/US20170232006A1/en not_active Abandoned
-
2018
- 2018-07-03 CY CY20181100686T patent/CY1121150T1/el unknown
- 2018-07-05 HR HRP20181048TT patent/HRP20181048T1/hr unknown
- 2018-08-14 AU AU2018217213A patent/AU2018217213B2/en active Active
-
2019
- 2019-05-22 US US16/419,255 patent/US20200113916A1/en not_active Abandoned
- 2019-06-12 JP JP2019109822A patent/JP6852118B2/ja active Active
-
2020
- 2020-03-20 AU AU2020202016A patent/AU2020202016C1/en active Active
- 2020-10-29 IL IL278396A patent/IL278396B2/en unknown
-
2021
- 2021-03-10 JP JP2021038515A patent/JP7241792B2/ja active Active
- 2021-06-21 US US17/304,433 patent/US20210308149A1/en active Pending
- 2021-12-20 AU AU2021290223A patent/AU2021290223B2/en active Active
-
2023
- 2023-02-09 US US18/107,965 patent/US20230190770A1/en not_active Abandoned
- 2023-03-07 JP JP2023034402A patent/JP2023071910A/ja active Pending
-
2024
- 2024-04-08 AU AU2024202233A patent/AU2024202233A1/en not_active Abandoned